This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Implied Volatility Surging for Genocea (GNCA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Genocea (GNCA) stock based on the movements in the options market lately.
Do Options Traders Know Something About Genocea (GNCA) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Genocea (GNCA) stock based on the movements in the options market lately.
Genocea (GNCA) Begins Phase I/IIa Study for Solid Tumor Drug
by Zacks Equity Research
Genocea Biosciences (GNCA) doses the first patient in phase I/IIa study on its investigational neoantigen-targeted T-Cell therapy, GEN-011, for solid tumors
Is the Options Market Predicting a Spike in Genocea (GNCA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Genocea (GNCA) stock based on the movements in the options market lately.
Genocea Biosciences (GNCA) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Genocea Biosciences (GNCA) delivered earnings and revenue surprises of 15.00% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for April 13th
by Zacks Equity Research
ASC, BCEI, XOG, GNCA, and GNLN have been added to the Zacks Rank #5 (Strong Sell) List on April 13, 2021
Is the Options Market Predicting a Spike in Genocea (GNCA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Genocea (GNCA) stock based on the movements in the options market lately.
Is Genocea Biosciences (GNCA) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (GNCA) Outperforming Other Medical Stocks This Year?
Genocea to Initiate a Phase I/II Oncology Study on GEN-011
by Zacks Equity Research
Genocea's (GNCA) investigational new drug application to initiate a clinical study to evaluate its neoantigen-specific cell therapy candidate, GEN-011 in cancer patients gets FDA clearance.
Are Options Traders Betting on a Big Move in Genocea Biosciences (GNCA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Genocea Biosciences (GNCA) stock based on the movements in the options market lately.
New Strong Buy Stocks for April 30th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Bet on Rising P/E Investing With These Top 5 Stocks
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.
Genocea Biosciences, Inc. (GNCA) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Genocea Biosciences, Inc. (GNCA).
Genocea Biosciences Enters Oversold Territory
by Zacks Equity Research
Genocea Biosciences has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Buy These 7 Small Drugmakers to Boost Your Portfolio's Health
by Kinjel Shah
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.
Are Options Traders Betting on a Big Move in Genocea Biosciences (GNCA) Stock?
by Zacks Equity Research
Investors need to pay close attention to Genocea Biosciences (GNCA) stock based on the movements in the options market lately.
Top Ranked Momentum Stocks to Buy for March 20th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 20th
Will Genocea Biosciences Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Genocea Biosciences.
Top Ranked Momentum Stocks to Buy for March 7th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 7th
Genocea Biosciences Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Genocea Biosciences has been struggling lately, but the selling pressure may be coming to an end soon.
Genocea Biosciences (GNCA) Jumps: Stock Rises 24.8%
by Zacks Equity Research
Genocea Biosciences (GNCA) was a big mover last session, as the company saw its shares rise almost 25% on the day amid huge volumes.
Are Options Traders Betting on a Big Move in Genocea Biosciences (GNCA) Stock?
by Zacks Equity Research
Investors in Genocea Biosciences (GNCA) need to pay close attention to the stock based on moves in the options market lately.
GENOCEA BIOSCIENCES (GNCA) Catches Eye: Stock Gains 7.1%
by Zacks Equity Research
GENOCEA BIOSCIENCES, INC. (GNCA) moved big last session, as its shares rose over 7% on the day.
Genocea Biosciences (GNCA) Jumps: Stock Moves 12% Higher
by Zacks Equity Research
Genocea Biosciences, Inc. (GNCA) shares rose almost 12% in the last trading session.
Should You Sell Genocea Biosciences (GNCA) Before Earnings?
by Zacks Equity Research
Investors are always looking for stocks that are poised to beat at earnings season and Genocea Biosciences, Inc. (GNCA) may be one such company.